- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04949386
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
A Randomized, Placebo-Controlled Phase II Study To Evaluate The Safety, Tolerability And Efficacy Of S-1226 In Post-Covid-19 Subjects With Persistent Respiratory Symptoms.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a randomized, placebo-controlled, phase II proof of concept study to evaluate the safety, tolerability and efficacy of S-1226 in Post-COVID-19 subjects (n≤48) with persistent respiratory symptoms.
S-1226 contains a potent, safe and well-tolerated bronchodilator gas (extrinsic carbon dioxide or CO2) and perflubron (PFOB), a synthetic surfactant that facilitates restoration of surfactant function and mucus clearance. The inhaled S-1226 combination of gas, vapor and liquid aerosol penetrates obstructed airways, resulting in rapid bronchodilation, enhanced blood oxygenation, improved mucus clearance and reduction of work of breathing.
Primary objective of this study is to evaluate the safety and tolerability of S-1226 composed of perflubron with 8% carbon dioxide in subjects with persistent post acute COVID-19 respiratory symptoms. The secondary objective is to establish proof of concept that S-1226 is effective in normalizing lung symptoms, including cough, breathlessness and lung function in subjects with persistent post-acute COVID-19 respiratory symptoms.
The study will consist of three parts: screening and randomization period, Treatment and evaluation, follow up period.
- Screening, and randomization: subjects will be randomized (1:1) to either receive placebo or S-1226 treatment.
- Treatment and evaluation period: subjects will receive either placebo -medical grade air with 3ml saline (0.9% NaCl) - or S-1226 (8% CO2) for 7 days twice daily. A single dose of S1226 (8%) will be administered over 3-4 minutes at each visit. Subjects will have the option to receive at home treatments once they been trained and verified as competent in handling study equipment.
- A follow up period 7 days after final treatment.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects must meet the following criteria to be included in the study:
- Male or Females between 18 -80 years of age at the time of consent
- Able to provide informed consent.
- Prior confirmed COVID-19 diagnosis by standard Real time Polymerase Chain Reaction (RT-PCR) assay or Immunoglobin M/G (IgM/IgG) rapid serological test at least 4 weeks prior to screening visit.
- Ambulatory patients may be attending COVID long term follow up clinic or discharged from hospital for at least one week.
- Evidence of new and/or persistent respiratory symptoms at least 4 weeks after the onset of acute COVID-19 infection. This will be determined by history of respiratory symptoms: cough, wheeze, limitation of activities.
- Able to perform an exercise of moderate activity e.g., walking up a hill or climbing stairs (required to assess Borg RPE)
- Able to walk unaided for a minimum distance of 10 meters (distance validated for completion of 6-minute walk test)
Exclusion Criteria:
Subjects to whom any of the following applies will be excluded from the study:
- Pregnancy or of childbearing age without a highly effective method or at least two forms of effective contraception and/ or abstinence for the duration of study. Highly effective methods of contraception (Contraception with < 1% failure rate) are: hormonal contraceptives (e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants); intrauterine device (IUD) or intrauterine system (IUS); vasectomy and tubal ligation. Effective methods of contraception may include barrier methods of contraception (e.g., male condom, female condom, cervical cap, diaphragm, contraceptive sponge).
- Breastfeeding females.
- Evidence of active thromboembolic disorder - defined by those receiving parenteral anticoagulant or thrombolytic therapy.
- Pre-existing evidence of unstable angina and myocardial infraction during the previous month, contraindications to the 6MWT.
- Subject, who in the opinion of the Investigator, is unsuitable to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with S-1226 (8%)
Subjects randomized to this treatment arm will receive S-1226(8%) twice daily for 7 consecutive days.
S-1226 will be administered by inhalation for 3-4 minutes.
|
S-1226 has two components delivered by inhalation.
It is a mixture of perfluorooctylbromide (PFOB) delivered in gas/aerosol/vapor form within a medical gas mixture containing 8% CO2.
Other Names:
|
Placebo Comparator: Placebo
Subjects randomized to receive placebo will be administered with medical grade air with 3ml saline (0.9% NaCl) using the Circulaire II hybrid system.
Placebo will be administered by inhalation for 3-4 minutes.
|
Placebo will delivered by inhalation of saline (0.9% NaCl) and Medical grade air.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Emergent Adverse Effects
Time Frame: 16 days
|
The number and percent of treatment emergent adverse events will be monitored, recorded and graded for severity and assigned attribution. The severity will be assessed in the following manner: Mild: Awareness of signs or symptoms, but are easily tolerated and are of minor irritant type, causing no limitations of usual activities. Signs or symptoms may require minor action or additional therapy. Moderate: Discomfort severe enough to cause some limitations of usual activities and may require action or additional therapy. Severe: Incapacitating with inability to carry out usual activities and requires specific action and/or medical attention. Note: the term severe is not the same as "serious", which is based on subject/event outcome or action criteria usually associated with events that pose a threat to a subject's life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations. |
16 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Normalization in 6-minute walk test (6MWT) distance
Time Frame: 16 days
|
Changes in induced shortness of breath will be monitored using the 6 Minute walk test (6MWT) with continuous oxygen saturation (SpO2) monitoring .
Normalization will be assessed by a return to normal distance values established in the literature.
|
16 days
|
Changes in percent predicted forced expiratory volume in 1 second
Time Frame: 16 days
|
Change from baseline in percent of predicted forced expiratory volume in 1 Second (FEV1) will be calculated by measuring FEV1 at baseline and after treatment.
FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.
|
16 days
|
Changes in from baseline in respiratory symptoms assessed by the St George's Respiratory Questionnaire (SGRQ).
Time Frame: 16 days
|
St George's Respiratory Questionnaire (SGRQ), a two-part questionnaire that evaluates participant symptoms, including cough, (part 1) and activities and impact (part 2).
Scores range from 0 to100 with higher scores indicating more limitations/perceived distress.
Scores will be compared to the established minimally clinically important difference (MCID).
|
16 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Forced Vital Capacity.
Time Frame: 16 days
|
Change from baseline in Forced Vital Capacity (FVC) will be measured.
FVC is the total volume of air that can be exhaled during a maximal forced expiration effort.
|
16 days
|
Changes from baseline in Diffusing Lung Capacity
Time Frame: 16 days
|
Changes from Baseline in Diffusing lung capacity (DLCO) will be measures.
DLCO is a measurement used to evaluate the lungs ability to transfer gas from inspired air to the bloodstream.
|
16 days
|
Changes from baseline in Oxygen Saturation (SpO2)
Time Frame: 16 days
|
Changes from baseline in percent of oxygen saturation (measured by pulse oximetry) will be calculated by measuring oxygen saturation before and up to 30 minutes after treatment.
|
16 days
|
Changes in from baseline in respiratory symptoms assessed by the modified Medical Research Council (mMRC) scale of dyspnea during daily activity.
Time Frame: 16 days
|
The modified Medical Research Council (mMRC) scale of dyspnea used assess baseline and subsequent activity related dyspnea.
Scores range from 0-4, with increasing scores representing greater difficulty in performing daily activities.
|
16 days
|
Changes in from baseline in respiratory symptoms assessed by the Borg Rating of Perceived Exertion (RPE) for dyspnea during exertion.
Time Frame: 16 days
|
Borg Rating of Perceived Exertion (RPE) a categorical scale used to assess dyspnea during exertion.
The lowest score, 6, represents No exertion/effort at all while the highest score of 20 represents absolute maximal effort/exhaustion.
|
16 days
|
Changes in from baseline in respiratory symptoms assessed by Visual Analogue Scale (VAS) for dyspnea while at rest.
Time Frame: 16 days
|
A 10 cm Visual Analogue Scale (VAS) to assess participant dyspnea while at rest at the time of Assessment.
Three delineations will be placed on the scale (0 being no dyspnea, 5 (middle) and 10 being max dyspnea) for participants to mark with a cross.
|
16 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- El Mays TY, Choudhury P, Leigh R, Koumoundouros E, Van der Velden J, Shrestha G, Pieron CA, Dennis JH, Green FH, Snibson KJ. Nebulized perflubron and carbon dioxide rapidly dilate constricted airways in an ovine model of allergic asthma. Respir Res. 2014 Sep 16;15(1):98. doi: 10.1186/s12931-014-0098-x.
- Swystun V, Green FHY, Dennis JH, Rampakakis E, Lalli G, Fadayomi M, Chiu A, Shrestha G, El Shahat SG, Nelson DE, El Mays TY, Pieron CA, Leigh R. A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma. Trials. 2018 Jun 18;19(1):321. doi: 10.1186/s13063-018-2720-6.
- Green FH, Leigh R, Fadayomi M, Lalli G, Chiu A, Shrestha G, ElShahat SG, Nelson DE, El Mays TY, Pieron CA, Dennis JH. A phase I, placebo-controlled, randomized, double-blind, single ascending dose-ranging study to evaluate the safety and tolerability of a novel biophysical bronchodilator (S-1226) administered by nebulization in healthy volunteers. Trials. 2016 Jul 28;17:361. doi: 10.1186/s13063-016-1489-8.
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAMi-06-1-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Acute COVID-19 Syndrome
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Azienda Socio Sanitaria Territoriale di LeccoRecruitingPost Acute COVID-19 SyndromeItaly
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Massachusetts General HospitalRecruitingDysexecutive Syndrome | Post-Acute Sequelae of COVID-19United States
-
Adhera Health, Inc.Institut Català de la Salut; Andaluz Health ServiceCompletedFatigue | Post-Acute COVID19 SyndromeSpain
-
Leiden University Medical CenterUniversity Medical Center Groningen; UMC Utrecht; Academisch Medisch Centrum... and other collaboratorsRecruitingCOVID-19 | Post-Acute COVID19 Syndrome | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Post COVID-19 Condition | Multi-System Inflammatory Syndrome in Children | Pediatric Inflammatory Multisystem SyndromeNetherlands
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Timothy HenrichShionogi Inc.Enrolling by invitationLong COVID | Post-Acute COVID-19 | Post Acute Sequelae of COVID-19United States
Clinical Trials on S-1226 (8%)
-
SolAeroMed Inc.RecruitingBronchiectasis | Cystic FibrosisCanada
-
SolAeroMed Inc.SuspendedCovid19 | SARS-CoV-2 InfectionCanada
-
Nabi BiopharmaceuticalsVanderbilt UniversityCompleted
-
Nabi BiopharmaceuticalsCompletedStaphylococcal Infections | Joint ProsthesisUnited States
-
Nabi BiopharmaceuticalsCompletedStaphylococcal Infections | Chronic Kidney FailureUnited States
-
University of California, San FranciscoActive, not recruitingParkinson Disease | DystoniaUnited States
-
Nabi BiopharmaceuticalsCompletedKidney Failure, Chronic | Staphylococcal Infections
-
Nabi BiopharmaceuticalsCompletedCardiovascular Diseases | Staphylococcal Infections | Cardiovascular Surgical ProceduresUnited States
-
Nabi BiopharmaceuticalsPublic Health EnglandCompletedStaphylococcal InfectionsUnited Kingdom
-
University of OxfordNational Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...CompletedPlasmodium Falciparum MalariaUnited Kingdom